Tetraphase Pharmaceuticals is a clinical-stage life science company with a groundbreaking synthetic chemistry technology platform that has the power to deliver solutions to the global health crisis caused by antibiotic resistance. The Company has developed a robust antibiotic franchise that offers the potential to dramatically improve the treatment of both broad and selective spectrum bacterial infections.

Doug Cole is on the Board of Directors.